MINNEAPOLIS, May 18, 2021 /PRNewswire/ — Imbio, a leading medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and Riverain Technologies™, a leader in clinical AI for lung nodules, announce […]
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of […]
MINNEAPOLIS, April 6, 2021 /PRNewswire/ — Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, and Heart&Lung Health, a leading cardiothoracic consultancy firm, announced their partnership to integrate Imbio AI algorithms […]
MINNEAPOLIS, March 16, 2021 /PRNewswire/ — Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RV/LV Analysis™ algorithm. The […]
MEMPHIS, Tenn., Feb. 24, 2021 /PRNewswire/ — Spesana, a healthcare platform focused for molecular diagnostics-driven decision support and clinical collaboration, and Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging […]
AI-based Software Providing Physicians with Quantitative Evaluation of CT Scans (QCT) for the Non-invasive Determination of Patient Eligibility for the Spiration Valve System Procedure to Treat Severe Emphysema CENTER VALLEY, […]
Accumen is helping healthcare get better, faster. Today, 3DR Labs, an Accumen Company, announced that it is now offering an artificial intelligence (AI) solution for diagnosing chronic lung disease through a new partnership with Imbio. 3DR Labs customers will have access to Imbio’s AI imaging technology effective immediately.
Aidoc, the leading provider of enterprise AI solutions, and Imbio, a leading provider of medical image analysis for pulmonary and cardiothoracic diseases, announced today a partnership intended to provide the world’s first end-to-end AI solution for pulmonary embolism (PE), with the goal of ultimately improving efficiency and quality of pulmonary embolism detection and treatment.
Imbio and Siemens Healthineers announced they are partnering to expand access to Imbio AI algorithms worldwide. Physicians will now be able to apply Imbio’s automated AI for quantitative image analysis directly through the Open Apps interface on Siemens’ syngo.via platform.
MINNEAPOLIS, Oct. 6, 2020 /PRNewswire/ — Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging […]